Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Dr. Prashant Pandya
Program Management,
Reliance Life Sciences,
Mumbai,
India
Dr. Prashant Pandya is GM, Program Management at Reliance Life Sciences, Mumbai, India. He has over 18 years of research experience (Academic & Industry) in various fields such as First in human studies, Stem cell research, Phase-II-IV clinical trials, Bioequivalence and QTC studies. He also serves as an Editorial Board member for the “Chronicles of Pharmaceutical Science” and United Nations Educational, Scientific and Cultural Organization (UNESCO) -Chair in Life Sciences) representative to India to promote Research and Post Graduate/Doctorate education in developing countries. He has monitored and conducted more than 200+ national and global studies and has hands-on experience in the complete drug development process. He is a qualified Pharmacist, certified Project Manager & clinical research professional from Canada with Doctorate work in Pharmaceutical & Business Management. He was visiting fellow at Stanford University, USA during 2011-12. He has received numerous industry honors and awards including: ♦ RLS -Leader of the Year award for outstanding contribution & upholding the value of Reliance Life Sciences -Year 2013 ♦ Best Student -Star award from APARC, Stanford University. Year 2012 ♦ Winner of National Scholarship –Sponsored by Govt. of India, Year 1993 Prior to joining Reliance Life Sciences, he was associated with India’s leading pharmaceutical and Contract Research Organizations such as Ranbaxy & Cadila Pharmaceuticals Ltd. He has authored several national and International publications in reputed journals.
Human studies, Stem cell research, Phase-II-IV clinical trials, Bioequivalence and QTC studies
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals